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1 Photons and X-rays are used in the text to descri
opposed to protons, which we consider to be light
particles.
Open access undAlthough proton therapy has been used for many decades because of their superior dose distribution over
photons and reduced integral dose, their clinical implementation is still controversial. We updated a sys-
tematic review of charged particle therapy. Although still no randomised trials were identiﬁed, the ﬁeld is
moving quickly and we therefore also formulated ways to move forward. In our view, the aim should be
to build enough proton therapy facilities with interest in research to further improve the treatment and
to run the needed clinical trials.
 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Charged particle radiotherapy (CPT) has been under the spot-
light for many years. Investigators are looking for an answer to
the question: how does it inﬂuence the outcome of cancer patients
[1–3]? Based on the dose distributions, it has been concluded that
the use of protons may lead to improved coverage of the Planning
Target Volume (PTV) and reduced doses to many organs at risk
(OAR) [1–3].
Several systematic reviews performed during the last decade
[2,4–11] investigating the clinical efﬁcacy of CPT show that, for
most indications, no ﬁrm conclusions can be drawn. In part this
is due to a lack of high quality data, making adequate comparisons
impossible. In addition, cost-effectiveness analysis of this technol-
ogy also could not clearly demonstrate that CPT was more cost-
effective than the most advanced photon1 technology, such as
stereotactic body radiotherapy (SBRT or stereotactic ablative radio-
therapy, SABR) or intensity modulated radiotherapy (IMRT)
[8,10,12–16]. The published results generated a world-wide debate
between proponents and sceptics [13]. Because so many patients
have been treated with protons and C-ions world-wide, we
performed a new systematic review of the literature, 5 years after
our previous publication [10]. The full report is available on line as
a Supplementary ﬁle.
Our main goal was to explore to which extent previous recom-
mendations were taken up by the radiation oncology communityiation Oncology (MAASTRO),
iology, Maastricht University
Netherlands.
e Ruysscher).
be the same beam quality as
ions and 11C that are heavy
 er CC BY-NC-ND license.and to determine if it is possible to draw ﬁrm conclusions about
the clinical and cost-effectiveness of CPT as compared to best
current practice.
It was sobering to observe that no phase III trials have been per-
formed and from the many retrospective and the few prospective
series, we still cannot conclude that protons or C-ions are truly
superior to X-rays. Moreover, many of the available clinical studies
were performed at a time when the current proton techniques and
the newest X-ray treatment, including imaging and adaptation,
were not available. Our former conclusion thus still stands: except
for rare indications such as childhood cancer, the gain from intro-
ducing proton therapies into clinical practice remains controver-
sial. The contention that protons are more suitable when OAR
dose constraints limit the delivery of the most appropriate tumour
X-ray radiotherapy doses is compelling, but remains unproven. Nor
do we know if CPT allows radiation dose escalation without
increasing side effects – leading to improved local tumour control
and survival. Where dose escalation is achievable by the most
recent X-ray based techniques, the gain from proton therapy is con-
ﬁned to a reduction in dose to organs away from the target region.
These arguments depend on the accuracy of the predicted dose
distribution and sound estimates of the relative biological effec-
tiveness (RBE) values for the cancer and for each normal tissue [17].
The debate between the advocates in favour of randomised
studies for all circumstances, and those who consider this to be
unethical when reduced radiation dose can be delivered to OAR,
continues [18–23]. X-ray (photon) treatment and imaging
techniques have signiﬁcantly improved over recent decades with
increased implementation of IMRT, arc and helical treatment and
SABR in routine clinical practice [24–27]. Together with imaging
developments such as CT-, MRI- and PET-based radiotherapy
6 Systematic review charged particlesplanning, 4D-CT and improved dose calculation and optimisation
algorithms, X-ray therapy allows the delivery of radiotherapy to
high doses. Modern X-ray techniques in common malignancies
such as non-small cell lung cancer are comparable to, or even supe-
rior to, that of protons therapy delivered with passive scattering
techniques [28]. However X-ray techniques will always deliver a
higher integral dose than protons and there is concern about low
dose effects to a wider volume because of enhanced cancer induc-
tion and circulatory system risks [29–31]. At the same time proton
therapy has also signiﬁcantly improved, allowing the delivery of
Intensity Modulated Proton Therapy (IMPT) with commercial sys-
tems [3].
At present, many planning studies show that for the high dose
regions, the best available X-ray and proton treatments result in
similar dose distributions within and around the tumour. However
the medium and low dose volumes are smaller and receive less
radiation dose with IMPT than with any X-ray technique [30–35].
Proponents of protons view the data as a proof that ultimately pro-
ton therapy will supersede X-rays because it is generally agreed
that the ALARA (As Low As Reasonably Achievable) principle
should be followed [1]. Arguments against this viewpoint are that
a reduction of the medium and low dose volumes are not beneﬁcial
for the patient when only a shallow dose–response relationship be-
tween an intermediate dose and side-effects exists or when the
side effects are of no clinical relevance or occur in only a small pro-
portion of patients. Balanced arguments, considering many of the
technical aspects have been published recently (e.g. [36,37]). When
some OARs can be spared more effectively with protons than
X-rays, even for the medium or low dose levels, more effective
dose-escalation may be possible, either for radiotherapy or for
combined radiation and systemic treatment.
Because the absorption and range of protons is more dependent
on electron density inhomogeneity than X-rays, small shifts of the
tumour or of the OARs in areas with high density gradients, e.g. in
the lungs (where not only lung density but also tumour position
varies with breathing), may directly result in large changes and er-
rors in dose distribution. Adaptive radiotherapy techniques thus
become evenmore important for protons than for X-rays, and these
are in development for each modality [38,39]. Probability based
treatment planning strategies taking into account volume changes
and shifts of the tumour and the OARs have been described allow-
ing more robust dose distributions for scanned proton beams,
although there is a longer history of using respiratory gating tech-
niques in proton therapy than in the case of X-ray therapy [40].
If proton therapy can fulﬁl its initial promise it may well turn
out to be a cost-effective intervention [12]. It is necessary to break
the current vicious circle where the lack of robust clinical data
leads to a lack of evidence to support funding and further develop-
ment of proton beam therapy in state-of-the-art treatment centres
with responsibilities to produce robust clinical data [41,42]. The
root cause of the problem facing proton therapy is the historic fail-
ure to leverage the collection and sharing of anonymised data in
return for capital investment in what is, to all intents and purposes,
still a developing and experimental technology. Unless the present
culture is radically changed this collaborative failure will continue
to be proton therapy’s Achilles heel.
We believe that randomised phase III trials will be needed for
some, but not necessarily all, situations to investigate the role of
protons and their cost-effectiveness. Prospective phase II studies
using the best available techniques and reporting agreed endpoints
of clinical relevance are the minimum requirement. As recom-
mended previously, all studies should be fully integrated in large
international networks and databases to make reliable and rapid
progress: this needs urgent implementation.
New particle beam centres should be funded with a provision
for shared basic research, technical improvements and properlyconducted trials. An enhanced level of global, or at least continen-
tal or national, governance of particle therapy is of paramount
importance.
Only then, will we be in a position to clarify the real gain of CPT
and to bring an otherwise endless debate to an unequivocal
conclusion.Research support and disclaimer
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